Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART

Crespo, Manuel; Caragol, Isabel; Falcó, Vicenç; Ribera, Esteban; S, Urban; Pahissa, Albert

doi:10.1157/13114392

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An in vivo study using an immunocompetent BALB/c mouse model revealed that repeated application of rIL-2 significantly enhanced the antiviral effect of the low number of lymphocytes in several tissues, both in prophylaxis and in therapy (16). In a prospective cohort study on patients with HIV, CD4 + T-cell counts were observed to increase after rIL-2 treatment (17). Furthermore, a low dose of rIL-2 selectively modulated CD4 + T-cell subsets in patients with systemic lupus erythematosus and markedly reduced the activity of the disease (18).…”

Section: Discussionmentioning

confidence: 99%

Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19

et al. 2021

View full text Add to dashboard Cite

A recently identified type of pneumonia, referred to as coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2, has rapidly spread worldwide. Lymphopenia and a proinflammatory cytokine storm frequently occur in patients with severe COVID-19. However, to the best of our knowledge, no specific immunomodulatory therapy for COVID-19 has been reported to date. In the present retrospective case-control study, the potential therapeutic effect of recombinant human interleukin-2 (rIL-2) in patients with severe COVID-19 was demonstrated. A total of 59 patients with severe COVID-19 were admitted to the Union Hospital of Tongji Medical College (Wuhan, China) between 29th January 2020 and 29th February 2020 and were included in the present study. In total, 20 patients received subcutaneous injection of rIL-2 (1 million IU per day) for 7-10 days in addition to regular treatment and were classified as the rIL-2 group. Furthermore, 20 of the 39 patients receiving regular treatment, without the intervention of rIL-2, were matched as the control group. Patients in these two groups were subjected to propensity score matching in terms of clinical characteristics such as age, sex, symptoms, signs, laboratory data and comorbidities. Changes in the lymphocyte count, as well as IL-6 and C-reactive protein (CRP) levels, were analyzed at the time of admission and discharge and any differences between the rIL-2 and non-rIL-2 groups were determined. The results demonstrated an increase in the lymphocyte count and a decrease in CRP levels in the rIL-2 group compared with that in the non-rIL-2 group. The difference in the change of the lymphocyte count between the rIL-2 group and non-rIL-2 group was statistically significant (P<0.01). Although CRP levels were decreased to a greater extent in the rIL-2 group, the difference between the two groups was not statistically significant (P>0.05). Collectively, the present results suggested that administration of rIL-2 may be a prospective adjuvant therapy for patients with severe COVID-19 and its effects may be mediated by increasing lymphocyte numbers.

show abstract

Section: Discussionmentioning

confidence: 99%

Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Immunological discordance has been reported in 15-30z of patients who receive ART (15), and the risk factors for this condition are advanced age, low nadir CD4 ＋ cell count, hepatitis C virus (HCV) coinfection, and poor adherence to ART (15)(16)(17)(18). There are several controlled studies regarding immunological responses in HIV patients using interleukin (IL)-2 and IL-7, some of which have demonstrated the effectiveness of immunotherapy (19,20). However, the benefits of immunotherapy remain unclear, and the United States Department of Health and Human Service guidelines have recommended that immune-based therapies should not be used unless in the context of clinical research (21).…”

Section: Introductionmentioning

confidence: 99%

Low Plasma Zinc Levels and Immunological Responses to Zinc Supplementation in HIV-Infected Patients with Immunological Discordance after Antiretroviral Therapy

2013

View full text Add to dashboard Cite

“…In this issue of EIMC, Crespo et al 23 report on a cohort of HIV-infected patients receiving combination antiretroviral therapy without a significant increase in CD4 count despite viral suppression below the limit of detection. In this study, patients with CD4 T cell counts below 200 who had received HAART for a median of nearly 5 years but showed no significant CD4 count increase for at least 12 months despite viral suppression to < 50 copies/mL, received low-dose, intermittent IL-2, consisting of IL-2 cycles (4.5 mIU once a day subcutaneously for 5 consecutive days) every 4 weeks with a planned goal of 6 cycles.…”

mentioning

confidence: 99%

HIV-infected immunologic non-responders: can we provide a helping hand?

Kovacs

2008

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART

Cited by 6 publications

References 24 publications

Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19

Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19

Low Plasma Zinc Levels and Immunological Responses to Zinc Supplementation in HIV-Infected Patients with Immunological Discordance after Antiretroviral Therapy

HIV-infected immunologic non-responders: can we provide a helping hand?

Contact Info

Product

Resources

About